Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
- S. Grösch, T. Maier, S. Schiffmann, G. Geisslinger
- Medicine
- Journal of the National Cancer Institute
- 7 June 2006
Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of… Expand
COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib
- S. Grösch, I. Tegeder, E. Niederberger, L. Bräutigam, G. Geisslinger
- Medicine
- FASEB journal : official publication of the…
- 1 December 2001
The regular use of various nonsteroidal anti‐inflammatory drugs (NSAIDs) was shown to decrease the incidence of colorectal cancer. This effect is thought to be caused predominantly by inhibition of… Expand
Chain length-specific properties of ceramides.
- S. Grösch, S. Schiffmann, G. Geisslinger
- Biology, Medicine
- Progress in lipid research
- 2012
Ceramides are a class of sphingolipids that are abundant in cell membranes. They are important structural components of the membrane but can also act as second messengers in various signaling… Expand
Apurinic endonuclease (Ref-1) is induced in mammalian cells by oxidative stress and involved in clastogenic adaptation.
Apurinic endonuclease (APE; also known as Ref-1 protein) is a key enzyme in base excision repair, cleaving apurinic sites that arise spontaneously because of the activity of DNA glycosylases. To… Expand
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.
- J. Lötsch, C. Skarke, S. Grösch, J. Darimont, H. Schmidt, G. Geisslinger
- Medicine
- Pharmacogenetics
- 2002
Large individual differences in the clinical response to morphine therapy have been known for a long time by clinicians. The recent advances in genomic research encourage the search for… Expand
G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation.
- I. Tegeder, S. Grösch, +5 authors G. Geisslinger
- Biology, Medicine
- Cancer research
- 15 April 2003
Opioid effects on tumor growth have been a controversial topic of discussion. In the present study, morphine inhibited tumor cell proliferation at concentrations of >or=10 micro M. This was primarily… Expand
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
- T. Maier, K. Schilling, R. Schmidt, G. Geisslinger, S. Grösch
- Biology, Medicine
- Biochemical pharmacology
- 15 April 2004
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-inflammatory drug so far which has been approved by the FDA for adjuvant treatment of patients with familial… Expand
BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis.
- B. Kaina, K. Ochs, +5 authors M. Christmann
- Biology, Medicine
- Progress in nucleic acid research and molecular…
- 2001
Methylating carcinogens and cytostatic drugs induce different methylation products in DNA. In cells not expressing the repair protein MGMT or expressing it at a low level, O6-methylguanine is the… Expand
Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling.
- I. Boldogh, C. V. Ramana, +6 authors B. Kaina
- Biology, Medicine
- Cancer research
- 1 September 1998
O6-Alkylguanine is the major mutagenic and cytotoxic DNA lesion induced by alkylating agents, including 2-chloroethyl-N-nitrosourea-based antitumor drugs. This lesion is repaired by… Expand
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB
- E. Niederberger, I. Tegeder, +6 authors G. Geisslinger
- Medicine
- FASEB journal : official publication of the…
- 1 July 2001
Celecoxib, a selective cyclooxygenase‐2 (COX‐2) inhibitor, has recently been approved for the symptomatic treatment of arthritis. In some clinical studies, doses of 400 and 800 mg/day provided… Expand